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risk group deﬁnitions lead to heterogeneity in CR rates. Only a small number of studies 
will provide valid estimates of the CR rates in patients with primary AML aged 16–60 
years. However, this restriction may reduce the reliability of the estimates, because 
the estimates will be based on fewer patients. This will thereby increase the uncertainty 
around the ICER of new methods.
PSY5
A RETROSPECTIVE CHART REVIEW OF THE TREATMENT OF 
PHENYLKETONURIA IN THE UK AND ASSOCIATED CLINICAL AND 
HEALTH OUTCOMES
Walters C1, Chauhan D1, Parkes L1, Chakrapani A2, MacDonald A2
1Merck Serono Ltd, Feltham, Middlesex, UK, 2Birmingham Children’s Hospital, Birmingham, 
UK
OBJECTIVES: To determine the proportion of phenylketonuria (PKU) patients 
managed successfully using current treatment strategies and to highlight a particular 
group(s) of PKU patients who may be uncontrolled by current treatment. METHODS: 
This is a non-interventional, retrospective, observational study. To date 4 UK sites 
have enrolled into the chart review. Information on patients with PKU or tetrahydro-
biopterin (BH4) deﬁciency was collected over a ﬁve year period (2004–2008). Data 
was collated on demographics, diagnosis, number of uncontrolled episodes, interven-
tions made during an uncontrolled episode and the length of time phenylalanine (Phe) 
levels were above the target level. An uncontrolled episode is deﬁned as three or more 
consecutive Phe levels above the National Society for Phenylketonuria (NSPKU) guide-
line. Interventions can include dietary advice, health care professional phone calls, 
clinic visits, counselling/psychological support, addition or change in use of supple-
ments, social care visits, and hospital admission. Data was analysed to explore the 
treatment of PKU in practice, the accompanying Phe levels and other health and clini-
cal outcomes. RESULTS: Recruitment is being completed. This information will be 
reported as a full dataset in the poster. Thus far data has been collected for 102 
patients across 3 centres (50% male). The age range of patients reviewed was 6–60 
years. A total of 93% of patients had a diagnosis of PKU, 0% BH4 deﬁciency and 
7% unknown. The average number of uncontrolled episodes per patient per year was 
1. An average of 7 interventions were made during each episode. The average length 
of the episode was 176 days. CONCLUSIONS: There is lack of published data on the 
management of PKU in clinical practice. This study provides an analysis of current 
treatment of PKU in clinical practice and its effectiveness on clinical and health out-
comes. The majority of PKU patients within this study had well-controlled Phe levels, 
however a number may beneﬁt from additional treatment.
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OBJECTIVES: Childhood obesity is a serious health problem favouring the early 
development of insulin resistance, type-2 diabetes mellitus and cardiovascular diseases. 
Our aim was to investigate multidisciplinary weight-control program applying exercise 
training at maximal fat oxidation (FATmax) zone and diet in three different duration 
on body composition and physical ﬁtness of overweight children. METHODS: Thirty 
overweight pupils (BMI  percentile 90%) of three different elementary schools (age: 
11.7 / 1.9) was included. Body composition was determined by bioelectric imped-
ance method. Graded exercise test (Jaeger Oxycon Pro) was used to determine whole-
body peak fat oxidation by indirect calorimeter. Training heart rate interval was 
determined by as / 10% of FATmax. Physical exercises were prescribed by the 
physiotherapist. Exercise training was performed 2 times /week in the school using 
heart rate monitor under the control of the games master. The training periods were 
56, 101 and 146 days. Dietary proposal was given for the parents of children by the 
dietetics. RESULTS: At the end of the weight-control program percentage of fat mass 
decreased (35.7 / 4.5 vs. 33.0 / 5.5%; p  0.001), muscle mass increased (22.8 
/ 4.6 vs. 24.4 / 5.2 kg; p  0.001). VO2max increased at the longest training 
period only (1841 / 620 vs. 2011 / 642 ml; p  0.043). CONCLUSIONS: Moder-
ate intensity exercise training and diet resulted in favourable changes in the body 
composition in a short term whereas the signiﬁcant improvement of VO2max was 
started only after 5 months training period.
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OBJECTIVES: To assess the impact of measures undertaken to improve data capture 
in the Fabry Outcome Survey (FOS). A physician-directed, multinational database 
established in 2001, FOS aims to advance the understanding and management 
of Fabry disease, a rare lysosomal storage disorder caused by deﬁciency of alfa-
 galactosidase A. METHODS: This initiative, supported by Shire HGT is driven by 
physicians in the management of Fabry disease. In 2006, additional measures were 
introduced to enhance the robustness of data capture: 1) a core dataset was developed 
for assessing disease progression and therapy response; 2) focus was directed at those 
participating centers with q20 patients enrolled in FOS; and 3) research associates 
were employed to monitor data capture and quality. Random samples (25%) of all 
enrolled patients were selected from the years 2004 and 2007, before and after the 
changes, respectively. The completeness of data capture was determined for 10 core 
variables in each year. RESULTS: Data capture was analyzed for 197 of the 815 
patients enrolled in FOS in 2004 and for 404 of the 1616 patients enrolled in 2007. 
Increases in data capture occurred for 9 of 10 core variables; the exception was patient 
weights, which were unchanged at 90% for both years. For key variables, the increases 
were: signs and symptoms, from 66% to 83%; serum creatinine, from 89% to 91%; 
left ventricular mass, from 48% to 55%; NHYA score, from 84% to 87%. In addition, 
the proportion of females enrolled increased from 48% to 54%. CONCLUSIONS: 
Focused efforts on improving data completeness and quality in FOS have been 
 successful, optimizing the value of the database. Regular, accurate data collection 
and audit will increase the quality of FOS data and lead to an improved understanding 
of the management of Fabry disease.
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OBJECTIVES: To evaluate the efﬁcacy and safety of tapentadol ER in patients with 
moderate-to-severe chronic low back pain. Health status was evaluated using SF-36 
and EQ-5D questionnaires. METHODS: Patients received controlled, adjustable 
twice-daily doses of tapentadol ER (100–250 mg), oxycodone HCl controlled release 
(CR; 20–50 mg), or placebo over a 12-week maintenance period, preceded by a 3-
week titration period. Patients completed the EQ-5D and SF-36 at baseline and at 
speciﬁed visits. EQ-5D evaluates mobility, self-care, usual activities, pain/discomfort, 
and anxiety/depression; SF-36 evaluates physical functioning, role-physical, bodily 
pain, general health, vitality, social functioning, role-emotional, and mental health 
dimensions. RESULTS: Of 981 patients randomized, 958 were evaluated for efﬁcacy. 
Compared with placebo, improvements from baseline to endpoint in the SF-36 physi-
cal component summary score were signiﬁcantly greater with tapentadol ER (least-
squares mean difference vs placebo [95% CI], 2.3[1.02,3.58], P  0.001) and 
oxycodone CR (2.3[1.02,3.56], P  0.001). Both active treatment groups were associ-
ated with signiﬁcant improvements over placebo in role-physical (tapentadol ER, 
9.9[4.21,15.49]; oxycodone CR, 9.4[3.83,15.05]; both P  0.001) and bodily pain 
(tapentadol ER, 5.5[2.44,8.55]; oxycodone CR, 6.3[3.23,9.29]; both P  0.001). 
Additionally, tapentadol ER was associated with signiﬁcantly better outcomes versus 
placebo in physical functioning (4.1[0.85,7.33], P  0.013) and vitality (3.2[0.41,6.01], 
P  0.025), while oxycodone CR was not signiﬁcantly different from placebo on these 
parameters (physical functioning, 2.6[−0.66,5.77], P  0.119; vitality, 0.8[−1.99,3.58], 
P  0.576). For both active treatment groups, changes from baseline in general health, 
social functioning, role-emotional, mental health, and mental health summary score 
did not differ signiﬁcantly from placebo (all P  0.285). Compared with placebo, the 
EQ-5D health status index at endpoint improved signiﬁcantly compared with baseline 
with tapentadol ER (0.05[0.01,0.09], P  0.020) and oxycodone CR (0.05[0.01,0.09], 
P  0.019). Incidences of treatment-emergent adverse events were placebo, 59.6%; 
tapentadol ER, 75.5%; and oxycodone CR, 84.8%. CONCLUSIONS: Tapentadol ER 
(100–250 mg bid) signiﬁcantly improved physical and overall health status in patients 
with moderate-to-severe chronic low back pain.
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OBJECTIVES: To examine predictors of adherence to duloxetine therapy and assess 
the association between adherence and health care costs among working-age patients 
with ﬁbromyalgia. METHODS: This study analyzed medical and pharmacy records 
for commercially-insured patients aged 18–64 diagnosed with ﬁbromyalgia who initi-
ated duloxetine between January 1, 2006 and December 31, 2006. The date of ﬁrst 
duloxetine prescription ﬁlled was deﬁned as the index date. Initiation of treatment 
was deﬁned as no pill coverage for duloxetine over the prior 90 days. All patients 
included had at least 30 days supply of duloxetine in the 12 months post-index period. 
Patients with diabetes peripheral neuropathic pain or depression in the 12 months 
pre-index period were excluded. Two study cohorts were constructed based on adher-
ence level to duloxetine (high adherence  medication possession ratio of  0.8). Pre-
dictors of high adherence were examined via logistic regression. Multivariate regression 
models were performed to examine the association between adherence and health care 
costs, controlling for demographics, clinical characteristics, and prior health care costs. 
RESULTS: A total of 4869 ﬁbromyalgia patients were identiﬁed, with a mean age of 
50 years and 88% female. Approximately 68% of duloxetine patients had low adher-
ence over the 12 months follow-up period. Higher average daily dose was associated 
with high adherence (reference group  30 mg; Odds Ratio  3.03, 2.40, and 3.74 for 
31–59 mg, 60 mg, and  60 mg, respectively; all p  0.05). Controlling for differences 
